MiNK Therapeutics Files 8-K for Equity Sale
Ticker: INKT · Form: 8-K · Filed: May 16, 2024 · CIK: 1840229
Sentiment: neutral
Topics: equity-sale, definitive-agreement
TL;DR
MiNK Therapeutics just sold unregistered equity, potentially raising cash.
AI Summary
MiNK Therapeutics, Inc. entered into a Material Definitive Agreement on May 13, 2024, related to the unregistered sale of equity securities. The company, formerly known as AgenTus Therapeutics, Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This filing indicates MiNK Therapeutics is raising capital through an unregistered equity sale, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can sometimes signal financial distress or be used for strategic capital raises, requiring further investigation into the terms and purpose.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former Name
- May 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices City
FAQ
What type of equity securities were sold in the unregistered sale?
The filing does not specify the type of equity securities sold in the unregistered sale.
What was the aggregate purchase price or total amount of the unregistered sales?
The filing does not disclose the aggregate purchase price or total amount of the unregistered sales.
Were any underwriters involved in this unregistered sale of equity securities?
The filing does not mention the involvement of any underwriters in the unregistered sale.
What is the purpose of this unregistered sale of equity securities for MiNK Therapeutics?
The filing does not state the specific purpose for the unregistered sale of equity securities.
When was the name of the company changed from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc.?
The date of the name change from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc. was January 12, 2021.
Filing Stats: 733 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-05-16 08:02:27
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Mar
- $1.25 — Common Shares"), at a purchase price of $1.25 per share, a 25% premium to the 30-day
- $5 — received net proceeds of approximately $5.8, after offering expenses. The transac
Filing Documents
- inkt-20240513.htm (8-K) — 38KB
- 0000950170-24-060805.txt ( ) — 153KB
- inkt-20240513.xsd (EX-101.SCH) — 25KB
- inkt-20240513_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. The disclosure set forth below under Item 3.02 is incorporated herein by reference.
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. On May 13, 2024, MiNK Therapeutics, Inc. (the "Company") entered into a Stock Purchase Agreement with a certain investor (the "Purchaser"), as identified on Exhibit A to the Stock Purchase Agreement, pursuant to which the Company issued and sold an aggregate of 4,640,000 shares of Common Stock (the "Common Shares"), at a purchase price of $1.25 per share, a 25% premium to the 30-day volume-weighted average stock price. The Company received net proceeds of approximately $5.8, after offering expenses. The transaction closed on May 14, 2024. The Stock Purchase Agreement requires the Company to register the resale of the Common Shares. The Company is generally required to prepare and file a registration statement with the Securities and Exchange Commission (the "Commission") on or before August 15, 2024, and to use commercially reasonable efforts to have the registration statement declared effective within 30 days if there is no review by the Commission, and within 90 days following receipt of written comments in the event of such review. In addition, the Purchaser has agreed not sell of any of the Common Stock prior to November 9, 2024 and to vote all of the shares of Common Stock that it then owns in accordance with the recommendation of the Company's board of directors on all matters presented to the Company's stockholders through May 14, 2025. The Common Shares were offered and sold without registration under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The Common Shares may not be offered or sold in the United States without an effective registration statement or pursuant to an exemption from applicable registration requirements. This Current Report on Form 8-K is not an offer to sell or the solicitation of an offer to buy the Securities. The ab
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 16, 2024 By: /s/ Jennifer Buell Jennifer Buell, CEO